NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Peking University Sixth Hospital, Peking University Institute of Mental Health, Beijing 100191, China; Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, International Joint Research Laboratory for Psychiatry and Neuroscience of Henan, Xinxiang 453002, China; Henan Collaborative Innovation Center of Prevention and Treatment of Mental Disorder, Xinxiang 453002, China.
Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, International Joint Research Laboratory for Psychiatry and Neuroscience of Henan, Xinxiang 453002, China; Henan Collaborative Innovation Center of Prevention and Treatment of Mental Disorder, Xinxiang 453002, China.
Neuroimage Clin. 2024;42:103603. doi: 10.1016/j.nicl.2024.103603. Epub 2024 Apr 3.
Antipsychotic drug treatment for schizophrenia (SZ) can alter brain structure and function, but it is unclear if specific regional changes are associated with treatment outcome. Therefore, we examined the effects of antipsychotic drug treatment on regional grey matter (GM) density, white matter (WM) density, and functional connectivity (FC) as well as associations between regional changes and treatment efficacy. SZ patients (n = 163) and health controls (HCs) (n = 131) were examined by structural magnetic resonance imaging (sMRI) at baseline, and a subset of SZ patients (n = 77) were re-examined after 8 weeks of second-generation antipsychotic treatment to assess changes in regional GM and WM density. In addition, 88 SZ patients and 81 HCs were examined by resting-state functional MRI (rs-fMRI) at baseline and the patients were re-examined post-treatment to examine FC changes. The Positive and Negative Syndrome Scale (PANSS) and MATRICS Consensus Cognitive Battery (MCCB) were applied to measure psychiatric symptoms and cognitive impairments in SZ. SZ patients were then stratified into response and non-response groups according to PANSS score change (≥50 % decrease or <50 % decrease, respectively). The GM density of the right cingulate gyrus, WM density of the right superior frontal gyrus (SFG) plus 5 other WM tracts were reduced in the response group compared to the non-response group. The FC values between the right anterior cingulate and paracingulate gyrus and left thalamus were reduced in the entire SZ group (n = 88) after treatment, while FC between the right inferior temporal gyrus (ITG) and right medial superior frontal gyrus (SFGmed) was increased in the response group. There were no significant changes in regional FC among the non-response group after treatment and no correlations with symptom or cognition test scores. These findings suggest that the right SFG is a critical target of antipsychotic drugs and that WM density and FC alterations within this region could be used as potential indicators in predicting the treatment outcome of antipsychotics of SZ.
抗精神病药物治疗精神分裂症 (SZ) 可改变大脑结构和功能,但尚不清楚特定区域的变化是否与治疗效果相关。因此,我们研究了抗精神病药物治疗对区域性灰质 (GM) 密度、白质 (WM) 密度和功能连接 (FC) 的影响,以及区域性变化与治疗效果之间的关联。SZ 患者(n=163)和健康对照组(HCs)(n=131)在基线时接受了结构磁共振成像(sMRI)检查,SZ 患者的一部分(n=77)在接受第二代抗精神病药物治疗 8 周后接受了再次检查,以评估区域性 GM 和 WM 密度的变化。此外,88 名 SZ 患者和 81 名 HCs 在基线时接受了静息状态功能磁共振成像(rs-fMRI)检查,患者在治疗后再次接受检查以检查 FC 的变化。阳性和阴性综合征量表(PANSS)和 MATRICS 共识认知电池(MCCB)用于测量 SZ 患者的精神症状和认知障碍。然后,根据 PANSS 评分变化(分别≥50%降低或<50%降低),将 SZ 患者分为反应组和非反应组。与非反应组相比,反应组的右侧扣带回 GM 密度降低,右侧额上回(SFG)加 5 个其他 WM 束的 WM 密度降低。整个 SZ 组(n=88)治疗后,右侧前扣带回和旁扣带回与左侧丘脑之间的 FC 值降低,而反应组右侧颞下回(ITG)与右侧内侧额上回(SFGmed)之间的 FC 值增加。治疗后,非反应组的区域 FC 没有明显变化,与症状或认知测试评分也没有相关性。这些发现表明右侧 SFG 是抗精神病药物的一个关键靶点,该区域内 WM 密度和 FC 的改变可作为预测 SZ 抗精神病药物治疗效果的潜在指标。